IP InterviewPublished March 10, 2024
Danaher: Cytiva's Bioprocessing Filtration Portfolio
inpractise.com/articles/danaher-cytivas-bioprocessing-filtration-portfolio
Executive Bio
Former VP of Sales at Pall Corp
Interview Transcript
Disclaimer: This interview is for informational purposes only and should not be relied upon as a basis for investment decisions. In Practise is an independent publisher and all opinions expressed by guests are solely their own opinions and do not reflect the opinion of In Practise.
This is a snippet of the transcript.to get full access.
If it's customized, can you only use Pall consumables? Or can you also use third-party consumables?
The core separation technology, such as the ultrafiltration membranes, could be from any company. It could be from Millipore. It could have been Repligen, or more often than not, it was not Pall. It was mostly Millipore and some Sartorius. Just due to market share, Pall's market share. They had legacy products from the Filtron days. But winning new market share was a struggle for them. They couldn't get it together.
Free Sample of 50+ Interviews
Sign up to test our content quality with a free sample of 50+ interviews.
Or contact sales for full access
Related Content
Thermo Fisher Scientific Inc: Culture and Management
Former Director at Thermo Fisher Scientific
Danaher, Aldevron, Intangible & Goodwill Impairments
Bruker and AI Applications in Mass Spectrometry
Former Director of Bruker
Porvair & Chromatography Lab Equipment: M&A Process & Culture
Former Senior Vice President Life Sciences at J.G. Finneran, Porvair plc
© 2024 In Practise. All rights reserved. This material is for informational purposes only and should not be considered as investment advice.